11,134 Shares in Ionis Pharmaceuticals Inc (IONS) Acquired by Opera Trading Capital
Opera Trading Capital acquired a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 11,134 shares of the company’s stock, valued at approximately $574,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. BB Biotech AG increased its stake in Ionis Pharmaceuticals by 1.8% in the 2nd quarter. BB Biotech AG now owns 8,666,334 shares of the company’s stock valued at $361,126,000 after buying an additional 150,000 shares during the period. Canada Pension Plan Investment Board increased its stake in Ionis Pharmaceuticals by 19.5% in the 2nd quarter. Canada Pension Plan Investment Board now owns 321,700 shares of the company’s stock valued at $13,405,000 after buying an additional 52,400 shares during the period. BlackRock Inc. increased its stake in Ionis Pharmaceuticals by 1.8% in the 2nd quarter. BlackRock Inc. now owns 7,054,579 shares of the company’s stock valued at $293,965,000 after buying an additional 124,233 shares during the period. Bellevue Group AG boosted its position in shares of Ionis Pharmaceuticals by 3.3% during the 2nd quarter. Bellevue Group AG now owns 322,586 shares of the company’s stock worth $13,442,000 after purchasing an additional 10,400 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Ionis Pharmaceuticals by 6.3% during the 2nd quarter. Bank of America Corp DE now owns 896,746 shares of the company’s stock worth $37,367,000 after purchasing an additional 53,503 shares in the last quarter. 85.87% of the stock is currently owned by institutional investors.
In related news, COO Brett P. Monia sold 16,493 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.00, for a total value of $890,622.00. Following the sale, the chief operating officer now directly owns 24,834 shares in the company, valued at approximately $1,341,036. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $49.54, for a total transaction of $619,250.00. Following the completion of the sale, the senior vice president now owns 31,896 shares in the company, valued at $1,580,127.84. The disclosure for this sale can be found here. 2.44% of the stock is owned by insiders.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. Ionis Pharmaceuticals had a negative net margin of 7.52% and a negative return on equity of 1.58%. The business had revenue of $145.40 million for the quarter, compared to analyst estimates of $146.77 million. During the same period in the previous year, the firm earned ($0.02) EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, research analysts expect that Ionis Pharmaceuticals Inc will post -0.19 EPS for the current fiscal year.
Several equities research analysts have commented on IONS shares. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Piper Jaffray Companies set a $50.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 6th. Morgan Stanley set a $46.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “hold” rating in a research report on Tuesday, September 25th. Finally, Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $54.00.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Featured Article: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.